NYXH ▼ -8.0% - Nyxoah SA $NYXH - Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System Nyxoah shares fell 8.0% despite the company announcing the first patient implantation in its BREATHE post-approval study for the Genio system in the U.S., a milestone that typically signals progress in commercializing its obstructive sleep apnea treatment. The decline suggests investors may have been pricing in this expected development or had concerns about broader market conditions unrelated to the announcement itself. 07-SEP-2026 04:05 PM ET